Table 2 Ranking of immunochemotherapy regimens by PFS.

From: Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Regimen

SUCRA

PbBT

PoRa [95% BCI]

G-Benda-G

0.97

72%

1 [1–3]

R-Benda-R4

0.88

25%

2 [1–5]

R-Benda-R

0.81

3%

3 [1–4]

G-CHOP-G

0.66

0%

4 [2–7]

R-CHOP-R

0.51

0%

6 [4–8]

R-Len-R

0.5

0%

6 [3–10]

R-Benda

0.48

0%

6 [4–8]

G-CVP-G

0.28

0%

8 [5–11]

R-CHOP

0.19

0%

9 [7–11]

R-CVP-R

0.16

0%

9 [7–11]

R-CVP

0.05

0%

11 [8–11]

  1. SUCRA surface under the cumulative ranking curve, PbBT probability of being the best treatment, PoRa posterior ranking, BCI Bayesian credible interval.
Back to article page